FDA Approves Tzield for Pediatric Type 1 Diabetes to Preserve Insulin Production

The U.S. Food and Drug Administration has given accelerated approval to Tzield (teplizumab) for a new use in pediatric patients. This treatment is now indicated to delay the decline of insulin production in children aged 8 to 17 who have been recently diagnosed with Stage 3 type 1 diabetes. This approval represents a significant advancement, offering the first FDA-approved treatment for this specific indication.